Canagliflozin vs FOXO4-DRI
A side-by-side research comparison of Canagliflozin and FOXO4-DRI across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | FOXO4-DRI |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | FOXO4-D-Retro-Inverso Peptide (Senolytic) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Research compound |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. |
| Molecular weight | 444.52 Da | ~4,500 Da |
| Half-life | ~11-13 hours | 12-24 hours (D-amino acid stability) |
| Bioavailability | ~65% oral | Moderate (SubQ) |
| Typical dose | 100-300 mg per day | 5-10 mg/kg (animal studies) |
| Frequency | Once daily | 3x per week for 3 weeks |
| Route | Oral tablet | Subcutaneous |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Related comparisons
Research and educational reference only. Not medical advice.